GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

Core Viewpoint - GT Biopharma, Inc. has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission regarding its Registration Statement on Form S-1, which was initially filed on December 23, 2024, and has not been declared effective [1] Company Overview - GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing immuno-oncology therapeutic products using its proprietary TriKE NK cell engager platform [3] - The TriKE platform aims to enhance the cancer-killing abilities of a patient's immune system's natural killer cells [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for further development and commercialization of therapies utilizing TriKE technology [3]